4 March 2026

THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION IN OR INTO AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH ITS DISTRIBUTION MAY BE UNLAWFUL

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED

Bellevue Healthcare Trust plc (the "Company")

Results of General Meeting

Change of Manager, Change of Name

Results of General Meeting

The Company announces that each of the Resolutions proposed at the general meeting of the Company held at 4.30 p.m. (London time) today (the "General Meeting") was duly passed.

Accordingly, the appointment of Columbia Threadneedle Investment Business Limited (together with its affiliates "Columbia Threadneedle") as the Company's AIFM and investment manager will become effective from 5 March 2026. The Company's name will be changed to "CT Healthcare Trust plc", with the ticker symbol CTHT as soon as possible.  A further announcement will be made when the change of name and ticker symbol are effective.

Resolutions were also passed to amend the Company's articles of association to remove the detailed provisions implementing the Redemption Facility previously operated by the Company and to approve the allotment and issue (or sale from treasury) for cash on a non-preemptive basis a number of Shares equal to 100 per cent. of the Shares in issue as at the date of this announcement (excluding Shares held in treasury), enabling the Company to grow in size and scale.

The Resolutions also included approval of the repurchase of up to 100 per cent. of the Company's ordinary redeemable shares of £0.01 each (the "Shares") in issue (excluding any Shares held in treasury) pursuant to the tender offer commenced on 12 February 2026 (the "Tender Offer"), further details of which are set out below.

Kate Bolsover, Chairman of the Company said:

"We are grateful for the significant support that shareholders have shown these proposals. We believe that the appointment of Columbia Threadneedle provides a highly differentiated and compelling opportunity to deliver long term risk adjusted shareholder returns from the healthcare and biotech sector."

Marrack Tonkin, Head of Investment Trusts at Columbia Threadneedle said:

"We are delighted to have secured the trust of shareholders to manage the Company on their behalf. We are excited to bring this proven strategy to a new market of investors and are keen to get started in building an investment portfolio designed to capture the upside of healthcare innovation and trends."

The results of the resolutions proposed at the General Meeting, each of which was held by poll, were as follows: 

*           Votes for include discretionary votes

**          A vote withheld is a not a vote in law and is not counted in the votes for or against a resolution

The full text of the resolutions can be found in the notice of the General Meeting contained in the Company's circular to shareholders dated 12 February 2026 (the "Circular"), which is available for inspection at the National Storage.Mechanism https://data.fca.org.uk/#/nsm/nationalstoragemechanism and also on the Company's website at www.bellevuehealthcaretrust.com/

Tender Offer

Further to the Tender Offer for up to 100 per cent. of the Shares in issue (excluding Shares held in treasury), launched by the Company on 12 February 2026 in connection with the Proposals, the Company also announces that 29,922,562 Shares were validly tendered pursuant to the Tender Offer, equal to approximately 40.9 per cent. of the 73,199,234 Shares in issue.

Eligible Shareholders who validly tendered Shares in the Tender Offer shall have all tendered Shares purchased in full under the Tender Offer in accordance with the process described in the Circular.

The price at which all tendered Shares will be acquired by the Company under the Tender Offer is 139.7186 pence per Share (the "Tender Price").

The Tender Price has been determined by reference to the Company's NAV per Share at close of business on the Calculation Date of 3 March 2026.

It is intended that the purchase of Shares under the Tender Offer will occur on or around 6 March 2026.

As described in the Circular, Threadneedle Asset Management Holdings Limited, or another UK subsidiary or affiliate of Ameriprise Financial Inc., intends to subscribe for up to the Sterling equivalent of $25 million of new Shares in the Company to support an appropriate level of scale and liquidity in the short to medium term following completion of the Tender Offer. A further announcement will be made in due course.

Capitalised terms not otherwise defined in this announcement shall have the meanings given to them in the Circular.

For further information, please contact: